Published in Medical Patent Law Weekly, February 7th, 2007
This trend article is an immediate alert from NewsRx to identify the most recent news developments at Ligand Pharmaceuticals.
Report 1: Ligand Pharmaceuticals, Inc., (LGND) announced that the company is initiating phase I clinical trials of LGD 4665, an oral, small-molecule drug that mimics the activity of thrombopoietin (TPO), a growth factor that promotes growth and production of blood platelets.
Thrombocytopenia or low platelet count is a common clinical finding associated with a diverse group of clinical disorders or conditions affecting...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Patent Law Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.